Overview
Retatrutide is an investigational single-molecule peptide agonist designed to engage three metabolic receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. It is sometimes described as a “triple agonist” or “triagonist” and represents an extension of the incretin-mimetic class beyond dual agonism.
Research interest in retatrutide stems from the hypothesis that adding glucagon receptor activity to dual incretin signaling may further increase energy expenditure and influence hepatic fat metabolism. It remains investigational and has not received regulatory approval.
Mechanism of action
Retatrutide combines agonism at three class B G-protein-coupled receptors. GLP-1 and GIP receptor activation enhance glucose-dependent insulin secretion and act on appetite and gastric emptying, while glucagon receptor activation is associated with increased energy expenditure, lipolysis, and hepatic glucose and lipid handling.
The theoretical advantage explored in research is that glucagon-driven increases in energy expenditure may complement the appetite-suppressing and insulinotropic effects of the incretin arms. Balancing these activities is central to the molecule’s design, since unopposed glucagon signaling could raise blood glucose; the peptide is engineered so incretin-mediated insulin secretion offsets this. The precise balance and long-term effects remain under active investigation.
Research findings
- Investigated in phase 1 and phase 2 clinical trials for body-weight reduction in adults with obesity, with dose-dependent reductions reported.
- Studied for glycemic effects in participants with type 2 diabetes.
- Examined for effects on hepatic steatosis and non-alcoholic fatty liver disease markers.
- Investigated for changes in lipid profiles and other cardiometabolic parameters.
- Mechanistic and dose-ranging research has explored the contribution of glucagon receptor agonism to overall metabolic outcomes.
Research context
Reported pharmacokinetics indicate a half-life on the order of roughly six days, consistent with once-weekly schedules used in trials. As an investigational compound, published dosing ranges and titration frequencies vary across studies and are generally escalated gradually at a high level to manage tolerability; details differ by trial. No regimen, concentration, or preparation information is provided here. This is a research reference only. These compounds are not approved for human use outside of regulated clinical settings; consult the primary literature.
Handling & storage
In laboratory use, the lyophilized peptide is generally stored frozen (commonly -20°C or colder), protected from light and moisture. Reconstituted peptide solutions of this class are typically refrigerated at 2-8°C and reported to have limited stability over time. Freeze-thaw cycling is generally avoided to preserve peptide integrity. No concentration or preparation guidance is provided.
Reported safety signals
Reported adverse effects in clinical research are predominantly gastrointestinal, including nausea, vomiting, diarrhea, and constipation, most common during dose escalation. Dose-dependent increases in heart rate have been reported, attributed in part to glucagon receptor activity. Other signals discussed in the literature include transient changes in glycemic and lipid markers. As an investigational agent, its long-term safety profile is not yet established.
Studied alongside
Retatrutide is typically discussed in research alongside other incretin-based agents, including the dual agonist tirzepatide and the GLP-1 receptor agonist semaglutide, as well as the GLP-1/glucagon dual agonist survodutide. The amylin analog cagrilintide is also referenced in the broader landscape of multi-mechanism metabolic compounds under study.
At a glance
Research strengths
- Triple-receptor mechanism studied for pronounced weight reduction in trials
- Glucagon arm investigated for added energy-expenditure effects
- Long half-life supports once-weekly study schedules
- Active area of cardiometabolic research
Limitations & cautions
- Investigational — not approved, long-term safety unestablished
- Dose-dependent heart-rate increases reported
- Gastrointestinal adverse effects common during titration
- Glucagon signaling adds complexity to metabolic balance
